A Study to Assess Regadenoson Administration Following an Inadequate Exercise Stress Test as Compared to Regadenoson Alone for Myocardial Perfusion Imaging (MPI) Using Single Photon Emission Computed Tomography (SPECT)
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1147 participants.
Also called NCT01618669
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking
- Phase
- Phase 3
- Enrolled
- 1,147 participants
- Sponsor
- Astellas Pharma Global Development, Inc.
- Registry
-
NCT01618669
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Argentina, Peru, Puerto Rico
- Registry status
- Completed
Technical summary
Registry record NCT01618669. Randomized; no masking. Start 2012-06 (registry gives no type); primary completion 2014-12 (actual). Results posted on 2016-02-08.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study to Assess Regadenoson Administration Following an Inadequate Exercise Stress Test as Compared to Regadenoson Alone for Myocardial Perfusion Imaging (MPI) Using Single Photon Emission Computed Tomography (SPECT)
- Acronym
- EXERRT
- Intervention (Drug)
- Regadenoson
- Intervention (Procedure)
- Single photon emission computed tomography (SPECT) myocardial perfusion imaging (MPI)
- Lead sponsor
- Astellas Pharma Global Development, Inc.
Record details
- Record id
cardio:ct-nct01618669- Content hash
ce0c4f7452efdecb16de36eb568282ca33fa72063b6c940f53a9646710ea2bb7